{"id":"W2954510583","doi":"10.1016/s1474-4422(19)30141-3","title":"Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"Ipsen; Deutsches Zentrum für Neurodegenerative Erkrankungen; H. Lundbeck A/S; Deutsche Stiftung Neurologie; NOMIS Stiftung; Roche; Deutsche Forschungsgemeinschaft; Deutscher Akademischer Austauschdienst; AbbVie; European Commission; Novartis; ParkinsonFonds Deutschland; Bundesministerium für Bildung und Forschung; Deutsche Parkinson Vereinigung; European Parkinson’s Disease Association; Bischof Dr. Karl Golser Stiftung; Teva Pharmaceutical Industries; Damp Stiftung; UCB; Arthur Arnstein Stiftung; Horizon 2020; Actelion Pharmaceuticals; Biogen; Michael J. Fox Foundation for Parkinson's Research","keywords":"Placebo; Double blind; Medicine; Gallate; Randomized controlled trial; Atrophy; Epigallocatechin gallate; Internal medicine; Pharmacology; Alternative medicine; Pathology; Chemistry; Antioxidant","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006544852,0.0002164418,0.001387517,0.0001246095,0.00004546921,0.000008410328,0.0001514036,0.0001351283,0.00003136652],"category_scores_gemma":[0.00007941997,0.0001312012,0.0001662367,0.0001284702,0.00006946194,0.000028102,0.00006761458,0.0002753677,0.00004535378],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000248181,"about_ca_system_score_gemma":0.00006129299,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008246332,"about_ca_topic_score_gemma":0.00002245133,"domain_scores_codex":[0.9982507,0.0003629351,0.0004905504,0.0003657961,0.0001768803,0.0003531514],"domain_scores_gemma":[0.998548,0.0005982854,0.000229554,0.0005022081,0.00002925702,0.00009274374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9904372,0.0002709555,0.006530682,0.0000989975,0.0002648004,0.0001076672,0.00008787565,0.0001109328,0.001224942,0.0005736112,0.000008257322,0.0002841113],"study_design_scores_gemma":[0.9833233,0.001628749,0.01132765,0.00004085535,0.0002741586,0.00006855203,0.000009180812,0.002601609,0.000198531,0.00005933683,0.0003748932,0.00009318406],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9893981,0.0003227764,0.00002261756,0.001265952,0.0003515204,0.007589353,0.00001147441,0.00005585249,0.0009824022],"genre_scores_gemma":[0.9990113,0.0001120148,0.00004061321,0.0002747142,0.0001642071,0.000261172,0.00001107603,0.00002579089,0.00009909269],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009613268,"threshold_uncertainty_score":0.535023,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02532264812165638,"score_gpt":0.2696299688208813,"score_spread":0.2443073206992249,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}